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ECG Arrhythmias and Technical Alarms during Left Ventricular Assist Device (LVAD)  
Therapy and its Potential Impact on Alarm Fatigue 
Kevin Watanakeeree 
Abstract 
Background: During alarm fatigue, true alarms can go unnoticed placing patients at risk for 
untoward outcomes. Patients with a left ventricular assist device (LVAD) may create challenges during 
electrocardiographic (ECG) monitoring due to technical alarms (i.e., artifact, ECG leads off), noise and 
vibrations associated with LVADs, and being able to tolerate some arrythmias. Clinical Nurse Specialists 
play a central role in and developing evidenced based strategies to improve alarm safety with the ultimate 
goal of improving patient outcomes.  Purpose/Aim: In this case series, we analyze three patients being 
treated with an LVAD device in the cardiac intensive care unit (ICU) and determine: 1) the number and 
type of audible arrhythmia alarms; 2) the number of true versus false arrhythmias; 3) the number, type 
and duration of technical alarms; and 4) report alarm burden. Methods: Secondary analysis using data 
from the University of California, San Francisco (UCSF) Alarm Study. Results: There were a total of 547 
arrhythmia alarms and 98% were false. There were 25,232 technical alarms. Of 514 total hours of ECG 
monitoring, technical alarms occurred for 65.9 (13%) hours. Conclusion: Audible arrhythmia alarms are 
common in LVAD patients, and the vast majority are false. Importantly, none of the arrhythmia alarms 
led to an untoward event (i.e., code blue or death). Technical alarms are also very common and occur for 
hours during routine ECG monitoring. Continuous ECG monitoring creates unique challenges in LVAD 
patients. Future studies are needed to explore strategies, both clinical and algorithm bases, to improve the 
accuracy of arrhythmia detection and minimize technical alarms in LVAD patients.    
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Background/Significance  
 Alarm safety is a National Patient Safety Goal established by The Joint Commission in 
2014.1,2  Clinical alarm systems are designed to alert busy caregivers about a change in a 
patient’s condition to avert adverse events. While this is the goal of alarms, previous research 
shows that patients in the Intensive Care Unit (ICU) yield large numbers of false or 
nonactionable alarms (i.e. true alarms but no action needed) creating an environment for alarm 
fatigue. Drew et al. reported, 90% of audible arrhythmia alarms in the ICU were false.3 In this 
study, and subsequent secondary data analyses, it was found that false alarms (i.e., incorrect 
detection of an arrythmia) were concentrated in select patients with the following characteristics 
including altered mental status, mechanically ventilated and in patients with certain 
electrocardiogram (ECG) features (i.e., bundle branch block [BBB], ventricular paced rhythms, 
and low amplitude QRS complexes).3–5  We hypothesize that patients with a left ventricular 
assist device (LVAD) may also have high rates of false arrhythmia alarms, as well as technical 
alarms (i.e., artifact, ECG/Respiratory leads fail and arrhythmia suspend) due to noise and 
vibrations associated with LVADs. These type of patients also commonly have the ECG features 
known to contribute to high numbers of alarms (i.e., left BBB, ventricular pacemaker), which 
means LVAD patients are likely to generate high numbers of alarms and contribute to alarm 
fatigue.  
In the study by Drew et al., it also reported of 2.5 million total alarms, 791,632 (32%) 
were technical alarms, which was a close second to premature ventricular complexes (n = 
869,000).3 Importantly, technical alarms may signal a problem that, if uncorrected, will lead to a 
complete suspension of arrhythmia detection. For example, if a technical alarm due to artifact 
continues, it will eventually trigger an ‘‘ARRHYTHMIA SUSPEND’’ alarm. This particular 
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alarm completely suspends all arrhythmia analysis, including lethal arrhythmias (i.e., asystole, 
ventricular fibrillation/tachycardia), placing patient’s in an unsafe situation because true alarms 
can go undetected. Surprisingly, there are very few studies that have examined technical alarms, 
and to our knowledge, no studies have looked at this specifically in the LVAD patient 
population. The paucity of literature may exist because some technical alarms are inaudible; 
hence, many believe these types of alarms do not contribute to alarm fatigue. However, while 
some technical alarms are inaudible text messages, such as artifact, others are audible (i.e., ECG 
leads off, and arrhythmia suspend), which alerts the nurse to correct the problem(s). In this case 
series analysis study, we examine both arrhythmia and technical alarms in three LVAD patients. 
While this is a small study, our data could help guide clinical and algorithm-based strategies to 
reduce false arrhythmia and/or technical alarms in this unique patient population.  
According to published data in 2019 from the American Heart Association, 
cardiovascular disease is the leading cause of death in the United States.6 This same data showed 
that over 6.2 million people have heart failure. Heart failure is a type of cardiovascular disease 
and the annual total cost of cardiovascular diseases in the United States is estimated to be $351.2 
billion. Patients with heart failure that worsens despite optimized medical management, along 
with a New York Heart Association classification (NYHA) for heart failure of IIIb to IV, are 
eligible for an LVAD.7 
What is a Left Ventricular Assist Device? 
  When a patient with an NYHA class IV heart failure is unable to efficiently sustain 
optimal cardiac output, an LVAD may be implanted in the torso to support circulation. The 
cannula, or inlet of the mechanical device, is typically placed in the apex of the failing left 
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ventricle. Oxygenated blood that would normally be pumped out of the left ventricle is instead 
pumped out via the LVAD and routed back to the aorta in order to supply oxygenated blood to 
the rest of the body. 8  The power supply for the LVAD is a percutaneous driveline wire that 
traverses the skin and connects to the external power system. The external components of an 
LVAD system consist of a power source (i.e., batteries or a hard-wire power supply) and a 
portable controller that controls pump speed, monitors device function and has programmed 
alarm settings.9 LVADs are typically categorized into two main types, pulsatile and continuous-
flow, or non-pulsatile. The pulsatile LVADs were created to mimic the pulsatile nature of a 
native heart while the continuous flow LVAD provides steady perfusion to the body.7  While 
first generation LVADs were designed as pulsatile, nearly all current devices are continuous flow 
(non-pulsatile). Of note, normal arterial blood pressure waveforms are typically tall, rounded and 
coincide with the ECG waveforms while the arterial waveform in a patient with an LVAD is flat, 
but still coincides with the ECG waveforms. Because patients with a non-pulsatile LVAD do not 
have the typical systolic and diastolic waveforms (Figure 1), nurses use the mean arterial 
pressure (MAP) to assess a patient’s perfusion status. Continuous-flow devices use either a 
centrifugal or axial-flow pump. Both types of continuous-flow devices have a central rotor 
containing permanent magnets. Electrical currents running through coils cause the rotors to spin. 
Rotors in the centrifugal pump accelerate the blood circumferentially, producing flow toward the 
outer rim of the pump; rotors in the axial-flow pump are cylindrical with blades that are helical, 
causing the blood to be accelerated along the axis of the rotors.7  
The physiologic condition of an end-stage heart failure patient with a non-pulsatile 
continuous flow LVAD is unique, in that the LVAD supports the patient’s cardiac output, yet 
generates no discernable or palpable pulse. The phenomenon of having “no pulse” creates a 
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challenging situation to healthcare providers many of whom are not trained to assess and treat 
this unique population of patients. According to the American Heart Association,10 in an event 
where resuscitation efforts may be required in an LVAD patient, emergency healthcare providers 
are to first assess signs of life which include mental status, ventilation, and perfusion (i.e. skin 
color, skin temperature, and capillary refill). This deviates from the process for non-LVAD 
patients, where Basic Life Support training recommends palpating for a pulse for ten seconds 
prior to initiating resuscitation. The second step of the American Heart Association algorithm for 
LVAD patients directs the healthcare provider to assess the LVAD for adequate functioning by 
restarting the LVAD, assessing the power supply, and auscultate for a humming sound that is 
generated by the LVAD. If providers are unable to troubleshoot the LVAD, chest compressions 
are initiated.   
The U.S. Food and Drug Administration (FDA) cites two indications for LVAD 
reimbursement by the Centers of Medicare and Medicaid Services (CMS). First, as a bridge to 
transplant, which is defined as a therapy while awaiting heart transplant. Secondly, as a 
destination therapy, defined as ongoing therapy when the patient is unable to meet transplant 
requirements including age >70 years, malignancy within the past 5 years and comorbidities, 
chronic renal failure, drug abuse, severe obesity, and fixed pulmonary hypertension.10,11 Studies 
show that there is a significant increase in survival when LVAD therapy is initiated. In the 
landmark REMATCH trial, which compared LVAD therapy to optimal medical therapy in 
patients with class IV heart failure, there was a 52% reduction in mortality among the LVAD 
group within the first year.10,12 Improved mortality, along with lengthening the time from 
diagnosis to transplant has made LVAD therapy increasingly more popular. According to the 
Interagency Registry for Mechanically Assisted Circulatory Support, there have been 22,866 
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mechanical circulatory support devices placed between 2006 and 2016, averaging over 2,500 
devices implanted per year. 13 As more LVADs are used each year, an ever-increasing body of 
research has emerged regarding the risks and benefits associated with these devices. As the use 
of LVADs increases, nurses need education about guideline-based interventions and guidance on 
how best to use and interpret ECG and physiologic monitoring data (i.e., blood pressure, pulse, 
respirations) in this patient population.  
 Complications associated with an LVAD device include driveline infections, 
strokes, gastrointestinal bleeding, circuit and pump thrombosis, and arrhythmias.8,14–16  Factors 
identified as contributing to high numbers of arrhythmia events during LVAD therapy include: 
1) high suction rates (decreased blood volume in the left ventricle causes the LVAD inlet to 
adhere to the sidewall of the left ventricle);  2) significant increases in body weight after LVAD 
implantation;  3) electrolyte imbalances; 4) development of myocardial scar tissue following 
placement; and 5) history of arrhythmias. However, because LVADs provide some degree of 
continuous support for cardiac output, assessment and treatment for arrythmias should be done 
on a case by case basis. Case reports demonstrate some LVAD patients are able to tolerate lethal 
arrhythmias (i.e., asystole, ventricular fibrillation [V-Fib], and ventricular tachycardia [V-Tach]) 
for a period of time due to the continuous blood flow produced by the LVAD.9,17–20 However, if 
the arrhythmias are prolonged, patients can have deleterious symptoms and dynamic vital sign 
changes that require prompt identification and intervention(s).   
Past studies have reported the presence of increased electrical ECG artifact and low 
amplitude QRS complexes associated with LVAD therapy.16,21 Published reports  indicate that 
some LVADs (HeartMate 3 and Heartware) create an electromagnetic field that interferes with 
pacemakers and ECG recordings causing 60-cycle interference.9,22 As shown in Figure 2, 60-
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cycle ECG interference can generate artifact alarms. Table 1, depicts current Practice Standards 
for In-hospital ECG Monitoring in patients with mechanical circulatory support, including 
LVADs. The practice standards identify ECG monitoring in the ICU for LVAD patients as a 
Class I recommendation, which means monitoring is indicated. However, we have anecdotal 
evidence that LVAD patients generate a high number of alarms for both technical and arrhythmia 
type alarms. Thus, while continuous ECG monitoring is indicated and standard practice in the 
ICU, the frequency of false arrhythmia and technical alarms, to our knowledge, has not been 
studied.      
Due to their unique role in the healthcare setting, Clinical Nurse Specialists (CNS) are at 
the forefront of developing strategies to improve alarm safety during ECG monitoring  The CNS 
role involves advanced knowledge in a specialty population, the ability to integrate evidence-
based practice into the clinical setting, functioning as a consultant across interdisciplinary teams, 
and supporting nursing staff. 23 This paper is written with the CNS role in mind with the goal of 
providing awareness and dialogue to CNSs with regard to ECG monitoring of this unique patient 
population. 
Purpose/Aim 
As outlined above, we hypothesize that patients with an LVAD are likely to generate 
high numbers of false arrhythmia and technical alarms, therefore creating an environment that 
may foster alarm fatigue. The purpose of this case review involving three ICU patients with an 
LVAD device is threefold what is: 1) the frequency and accuracy of audible arrhythmia alarms 
for asystole, v-fib, v-tach, accelerated ventricular rhythm, ventricular bradycardia, and pause; 2) 
the frequency and type of technical alarms for artifact, ECG/Respiratory leads fail, and 
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arrhythmia suspend; and 3) the alarm burden of these two types of alarms using the numbers of 
alarm/hour of ICU monitoring?    
Methods 
Setting and Design 
 This is a secondary analysis of data from the UCSF Alarm Study, the methods of which 
have been previously published.3  Briefly, the UCSF Alarm Study was a prospective 
observational study designed to examine the number and type of alarms from bedside 
physiologic monitors at a large tertiary-quaternary academic medical center. The technological 
infrastructure used in the study, captured all of the physiologic monitor data from each of the 77 
ICU beds over a one-month period. A total of three types of adult ICUs were including; cardiac 
medical/surgical and neurological. The study was approved by the UCSF Committee on Human 
Research with a waiver for patient consent since all ICU patients have physiologic monitoring as 
part of their routine care and our data was not used for clinical care or decision making, but 
rather examined retrospectively. This allowed us to collect data from 461 consecutive ICU 
patients. For this secondary analysis, we examine three patients who had an LVAD device in 
place. All three patients were admitted to the cardiac ICU.  
Physiologic Data Collection 
 All physiologic data and alarms were collected from bedside monitors (Solar 8000i; 
version 5.4 software, GE Healthcare, Milwaukee, WI). A research CARESCAPE Gateway 
system (GE Healthcare, Milwaukee, WI) was utilized to securely export the physiologic data to 
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an external server in order to conduct retrospective analysis (BedMasterEx; Excel Medical 
Electronics, Inc, Jupiter, FL).  All of the available physiologic monitoring data were captured 
including seven lead ECG leads (I, II, III, aVR, aVL, aVF and a V lead [V1 at our hospital]), 
arterial blood pressure, pulse oximetry and respirations. In addition to these data we captured 
numeric vital signs measurements, alarm parameter settings, both audible and inaudible 
arrhythmia alarms, parameter violations (i.e., blood pressure too high or low) and technical 
alarms (i.e., artifact, ECG/Respiratory leads off and arrhythmia suspend). The technical alarms 
were configured in the following manner with regards to audible versus inaudible; artifact = 
inaudible text message; ECG/Respiratory leads fail = warning (continuous foghorn tone); and 
arrhythmia suspend = warning (continuous foghorn tone). Our database represents one of the 
largest physiologic datasets available.  
Electrocardiographic Data and Annotation 
 Continuous ECG data was done using a five-electrode ECG lead configuration that 
recorded seven ECG leads (I, II, III, aVR, aVL, aVF, and V [V1 is used at our hospital]). 
Another unique feature of our database was that all of the 12,670 audible arrhythmia alarms were 
annotated as true or false, which we chose because these are more likely to contribute to alarm 
fatigue. The six audible arrhythmia alarms annotated were: asystole; v-fib; v-tach; accelerated 
ventricular rhythm; ventricular bradycardia; and pause. The annotation protocol (true vs. false) 
was performed by four PhD prepared nurse scientists using a standardized  protocol.3 ECG 
competency for each annotator was ensured by a formal 10-week ECG course each had taken 
and a 3-hour alarm annotation certification course taught by the principal investigator of the 
study. Inter-rater reliability among the annotators was 95% (Cohen’s Kappa score of 0.86). 
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Statistical Analyses 
 Data were analyzed using SPSS 26.0 (IBM Corporation, 2017). Descriptive statistics 
were used to examine frequencies for: 1) the number and type of audible arrhythmia alarms 
(asystole, v-fib, v-tach, accelerated idioventricular rhythm, ventricular bradycardia, and pause; 2) 
the number of true and false arrhythmia alarms; and 3) the number and type of technical alarms 
for artifact, ECG/Respiratory leads fail and arrhythmia suspend. The values are expressed as 
numeric numbers and percentages. Demographics and clinical history for the three patients will 
not be presented in order to maintain privacy, confidentiality and meet HIPAA standards.  
Results 
Frequency of Arrhythmias: A total of 547 audible arrhythmia alarms occurred in the three 
LVAD patients. Table 2 shows the audible arrhythmia alarms (total, type) and whether the 
arrhythmia was true or false. The most common type of arrhythmia alarm was for pause (n = 
307; 56%) and all were false alarms. The next most common alarm was for v-tach (n = 140; 
26%) and only 8 (6%) were true.  Figure 3 shows a false pause alarm. Figure 4 shows a true v-
tach alarm.  
Technical Alarms: Table 3 shows the technical alarms by type (i.e., artifact, 
ECG/Respiratory leads fail, and arrhythmia suspend) as well as the duration (hours). Artifact 
alarms were the most common and of longest duration; there were 23,427 unique alarms totaling 
to 22.6 hours. This was followed by ECG/Respiratory leads fail, with 854 and 821 respectively 
and duration 18.2 and 21.6 hours respectively. During the 514 total monitoring hours, technical 
alarms occurred for 66 hours (7.79%). Arrhythmia suspend (absence of arrhythmia analysis) 
occurred for 3.6 hours (0.7%).   
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Alarm Burden: The total number of monitored hours for all three LVAD patients was 514 
hours. As shown in Table 4, the number of technical alarms/hour of monitoring far exceeded the 
number of arrhythmia alarms/hour of monitoring (technical 49 alarms/hours of monitoring; 
arrhythmia 1.06 alarms/hour of monitoring). While patient #3 had the most alarms for both 
arrhythmias and technical issues (n = 10,913 of 25,779; 42%), when the number of alarms/hours 
of monitoring is used, patient #2 had the highest number (119 alarm/hour of monitoring). This 
was much higher than patient #1 (54.04 alarms/hour of monitoring) and patient #3 (37.54 
alarms/hour of monitoring).  
Discussion 
 This study appears to be the first to report on audible arrhythmia and technical alarms in 
LVAD patients. Despite a small sample, our study illustrates the alarm burden in this specific 
patient population, particularly with regards to technical alarms. The six annotated arrhythmia 
alarms (asystole, ventricular fibrillation, ventricular tachycardia, accelerated ventricular rhythm, 
ventricular bradycardia, and pause) were considered clinically important enough to be set as 
audible and, therefore, selected for analysis. The four technical alarms (artifact, ECG Leads fail, 
Respiratory Leads fail, and Arrythmia suspend) were analyzed due to their association with ECG 
monitoring. During a one-month time period, a small number of true arrhythmias occurred (2%), 
with eight for v-tach and one for accelerated ventricular rhythm. None of the patients had a code 
blue event or died. Technical alarms were by far the most common type of alarm (98%) as 
compared to arrhythmia alarms, with artifact being the most common type.  The overall alarm 
burden, measured using the number of alarms per monitored hour, was 50.15 alarms/monitored 
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hour. This means there was nearly one alarm every minute in these three patients, demonstrating 
the magnitude of alarm burden faced by nurses, LVAD patients and family members.  
Of the nine true arrhythmias, eight were for v-tach and one was for accelerated 
ventricular tachycardia. Each of the three LVAD patients had at least one true v-tach alarm. Two 
of the three also had false positive v-tach, with patient #3 having the most (105 alarms). A prior 
investigation identified v-tach as the most prevalent arrhythmia in LVAD patients and 
interestingly was shown to be well tolerated in most cases.24 Our findings supports this study in 
that none of the patients we examined had a code blue or rapid response call during their ICU 
stay. In previous studies, v-tach has been identified as an arrhythmia with a high rate of false 
positives and is corroborated in our study of LVAD patients.3 
The most common arrhythmia alarm was for pause, accounting for 56% of the total 
number of arrhythmia alarms. We identified one reason for this was low amplitude QRS 
complexes (Figure 4). Our group has identified this ECG feature as one that leads to high 
numbers of false alarms especially for asystole and pause.3–5 Patient #3, who had 77% of the 
total number of pause alarms, had a ventricular pacemaker; however, the “pacer-mode” feature 
had not been turned “on” – on the bedside monitor. This feature changes the ECG filter settings, 
which allows for better identification of pacer spikes and subsequent QRS detection. This one 
step could reduce false alarms in patients who have a ventricular pacemaker. In a prior study, we 
also found that not activating the pacer mode feature can lead to high numbers of false alarms for 
accelerated idioventricular ventricular rhythm (AIVR).25 We did not find this in our small sample 
of LVAD patients since only 28 total AIVR alarms occurred, which may suggest the pacer mode 
feature had been turned on at some point during monitoring. This does highlight the importance 
of nurse education related to the pacer-mode feature for in-hospital ECG monitoring. Patient #3 
 12 
was an outlier with regards to alarm frequency. This one patient had a total of 425 of the 538 
(79%) arrhythmia alarms. This particular patient had both low amplitude QRSs and a ventricular 
pacemaker, both of which are associated with high numbers of false alarms.3,4,25 
The most common technical alarm was for artifact, accounting for 93% of all technical 
alarms.  Technical alarms have been cited as one of the most commonly occurring alarm in 
multiple studies.3,26  While technical alarms are often configured as inaudible text message 
alarms, these flashing alerts can distract clinicians from patient care and contribute to alarm 
fatigue.27 What our study adds is a quantification of this problem. Of the 514 total hours of 
monitoring in just three LVAD patients, we found that technical alarms occurred for nearly 25 
hours, or 5% of monitoring. While there were substantially fewer alarms for ECG/Respiratory 
leads fail, the duration of these alarms was nearly that of artifact alarms (~ 20 hours). All 
technical alarm settings were unable to be changed or configured, therefore the factory default 
settings for the detection for technical alarms were used. It should be noted that these two types 
of alarms are configured as warning type alarms, which results in a continuous foghorn tone. 
This not only distracts nurses but may cause psychological anguish to patients and/or families 
who are already in distress.   
Most notably, and quite concerning was the nearly four hours of arrhythmia suspend, 
which means no arrhythmia detection due to sustained artifact. This could lead to missed true 
arrhythmia events and highlights how persistent artifact can impact patient safety. Worth noting, 
unlike artifact alarms, which are inaudible text message alarms, alarms for ECG/Respiratory and 
arrhythmia suspend alarms were all configured as audible alarms. One can see the serious risk 
this might create – well intentioned nurses making adjustments to volume setting in an attempt to 
reduce alarm fatigue and/or distress for patients and/or families. Unfortunately, this practice 
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places patients at risk for missed true events. It is not surprising that interventions aimed at 
reducing false alarms, particularly technical alarms, have included educational interventions 
about proper ECG skin electrode placement, careful skin preparation, daily electrode changes 
along with other strategies such as customizing alarm parameters, adjust default settings for all 
of the monitors on a unit. 3,26,28 How these might improve false alarms specifically in LVAD 
patients’ needs further study. 
We examined alarm burden by calculating the number of alarms per hour of monitoring. 
There was approximately one arrhythmia alarm/hour of monitoring for all three patients. 
However, the alarm burden from technical alarms was much high. For all three LVAD patients, 
there were 49 technical alarms/hour of monitoring. Of interests, was that patient #2 had the 
highest alarm burden (117 alarms/hour). This patient had a great deal of 60-cycle interference 
during their monitoring, with an extreme example shown in Figure 3. While this particular 
patient did not exhibit this same pattern throughout the entire monitoring period, “fuzzy” ECG 
waveforms were frequent and likely explains the extraordinary number of technical alarms in 
this one patient. What is not known is how our number of technical alarms compare to non-
LVAD patients and thus, should be examined in a future study. These data do show the high 
alarm burden from technical alarms experienced in LVAD patients albeit in a small sample.  
Limitations  
 The following limitations exist for this study: small sample size, single site location, and 
we do not report the LVAD type. Our data came from one ECG vendor, so how these alarms 
might occur in a different manufacturer is not known. This secondary analysis of a small number 
of LVAD patients highlights the large number of arrhythmia alarms that can occur, most of 
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which are false, and the extreme number of technical alarms caregivers are exposed to. Because 
this was a secondary analysis, we were not able to explore directly the consequences of alarm 
fatigue on nurses (i.e., prevalence or threshold level), patients and/or families (i.e., 
psychological, physiological) or potential impact on patient outcomes.   
Conclusion 
Audible arrhythmia alarms are common in LVAD patients, and the vast majority are 
false. None of the three patients we included had a rapid response, code blue event, or died 
during hospitalization, suggesting the arrhythmia were not life threatening. While the LVAD 
device supports cardiac output, there is considerable risk for lethal arrhythmias and thus, 
identification of these events with continuous ECG monitoring is important. Resuscitation efforts 
differ greatly in patients with an LVAD when compared to standard Basic Life Support 
protocols. Therefore, education about these difference is critical. Practice Standards for In-
hospital ECG monitoring state that ECG monitoring for LVAD patients treated in the ICU, is a 
Class I recommendations with a Level of Evidence C.17 Given our study findings, the 
development of specific strategies for this specific patient group, especially with regards to 
technical alarms, is warranted. This secondary analysis highlights the large number of both 
arrhythmia and technical alarms in LVAD patients. The CNS role lends itself well to generating 
evidence-based practice protocols to ensure that The Joint Commission’s National Patient Safety 
Goals for Alarm Safety are met.  
This paper calls for the attention of the CNS community to be mindful of this vulnerable 
population. The use of LVADs is increasing hence, evidence-based solutions are needed to 
mitigate conditions that contribute to alarm fatigue. Future studies are needed to understand and 
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analyze the relationship between LVADs and alarm fatigue, which will help guide strategies to 
improve identification of true arrhythmias while minimizing technical alarms. Our institution has 
developed a special LVAD profile for use in our bedside ECG monitor. We are in the process of 
determining if this profile reduces false alarms (both arrhythmia and technical) while 
maintaining accurate identification of actionable arrhythmias.   
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Figure 1, A and B. Illustrates an arterial blood pressure waveform in a patient without (A) 
and with (B) a left ventricular assist device (LVAD) along with the ECG waveform in lead 
II. A. Illustrates a normal arterial blood pressure waveform (bottom) that corresponds with 
the ECG waveform in lead II (top).  
 
B. Shown is a non-pulsatile waveform (bottom) that corresponds with the ECG waveform in lead 
II (top) but is much smaller in amplitude as compared to Figure A (above). The mean arterial 
blood pressure (MAP) is used in this situation. Of note is the “fuzzy” ECG waveform, which 
is not uncommon in LVAD patients. Note the premature ventricular complex (7th beat from 
the left) with loss of the arterial blood pressure waveform after this beat.  
Figure 1- Arterial Blood Monitor with and without LVAD 
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Figure 2. Example of 60-cycle interference on an electrocardiogram (ECG) obtained from the 
bedside monitor in a patient with a left ventricular assist device. Note the clean ECG signal in 
lead II, heart rate 105 beats/minute, and non-pulsatile arterial blood pressure waveform (bottom). 
The arterial blood pressure is 100/84 and the non-invasive blood pressure is 102/62. 
Figure 2- 60 Cycle Interference from LVAD 
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Figure 3. False pause alarm in a patient with a left ventricular assist device (LVAD). Note 
ventricular pacer spikes in front of every QRS complex best seen in lead III, aVL and aVF (~ 95 
beats/minute). The cause of this alarm is low amplitude QRS complexes. The algorithm requires 
a unidirectional (only positive or negative) QRS complex > 5 millimeters in two leads, using I, 
II, III or V1. Note, that the pacer mode feature was not turned on (Pace mode 0), which might 
have reduced these types of alarms.  
Figure 3-False Pause Alarm 
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Figure 4. True ECG alarm for ventricular tachycardia. Shown are ECG leads I, II, III, V, (V1), 
aVR, and arterial blood pressure (AR1) in a patient with a left ventricular assist device (LVAD). 
Note that the non-pulsatile arterial blood pressure waveform drops during the arrhythmia, but 
resumes once the rhythm subsides. Also of note, is the “fuzzy” ECG waveform in leads II and III 
common in LVAD patients.  
Figure 4-True Ventricular Tachycardia with LVAD 
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Table 1. Summary of current Practice Standards for In-hospital Electrocardiographic (ECG) 
Monitoring among patients with mechanical circulatory support, including left ventricular 
assist devices (LVADs).17 
Table 1-Summary of ECG Practice Standards 
 
Recommendation Classification of 
Recommendation and Level of 
Evidence 
Comments 
1. For hemodynamically 
unstable patients with 
immediate need for 
mechanical circulatory 
support, continuous 
arrhythmia is indicated. 
Class I; Level of Evidence C These patients will be in the 
intensive care unit (ICU); hence, 
it is standard of care to receive 
ECG monitoring to allow the 
recognition and treatment of 
arrhythmias. 
2. Arrhythmia monitoring 
is indicated for patients 
in the postoperative 
period after LVAD 
implantation. 
Class I; Level of Evidence C Used in the immediate post-
operative period following 
implantation; typically treated in 
the ICU. 
3. Arrhythmia 
monitoring can be 
beneficial for patients 
admitted with noncardiac 
problems but may not be 
needed in all 
circumstances if 
appropriate LVAD care 
can be provided. 
Class IIa; Level of Evidence C Hemodynamically stable 
patients admitted for non-cardiac 
problems (e.g., gastrointestinal 
bleed) will usually be treated on 
telemetry units. Continuous ECG 
monitoring is considered 
standard of care   because many 
patients have a pulse that is 
difficult or impossible to palpate; 
In addition, arrhythmias may 
provide insight into the 
hemodynamics of the VAD, 
indicating a need to increase or 
decrease pump speed to optimize 
hemodynamic function. 
4. Arrhythmia 
monitoring is not 
recommended for patients 
admitted to a rehabilitation 
facility where basic 
ventricular device care is 
available 
Class III: No Benefit; Level of 
Evidence C 
Rehabilitation facilities 
where staff is educated on the 
basic care of patients with VADs 
may be safe environments for 
these patients, even without 
providing continuous 
electrocar-diographic monitoring. 
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Table 3. Illustrates the type, number, and length (minutes) of technical alarms in patients with a 
left ventricular assist device 
Table 3- Technical Alarms 
LVAD 
Patient  
Monitor 
Hours 
Artifact ECG Leads Fail Respiratory 
Leads Fail 
Arrhythmia 
Suspend 
Total Alarms 
  Number Hours Number Hours Number Hours Number Hours Number Hours 
#1  182 9,395 8.3  208 4  201 4 32 0.7 9,836 16.8 
#2  42 3,925  3.2  483 2.3 461 5.7 43 1.7  4,912 12.9 
#3  290 10,107 11  163 12 159 12.1 55 1.1 10,484 36.3 
Total 514 23,427 22.6  854 18.2 821 21.6 130 3.6 25,232 65.9 
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